Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $76.4 million.

  • Orchestra BioMed Holdings' Cash from Financing Activities rose 40812.77% to $76.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.6 million, marking a year-over-year increase of 187924.03%. This contributed to the annual value of $29.2 million for FY2024, which is 3687.98% down from last year.
  • As of Q3 2025, Orchestra BioMed Holdings' Cash from Financing Activities stood at $76.4 million, which was up 40812.77% from -$428000.0 recorded in Q2 2025.
  • Over the past 5 years, Orchestra BioMed Holdings' Cash from Financing Activities peaked at $86.1 million during Q2 2022, and registered a low of -$10.7 million during Q4 2023.
  • Moreover, its 4-year median value for Cash from Financing Activities was $86000.0 (2023), whereas its average is $17.0 million.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Cash from Financing Activities surged by 37577500.0% in 2024 and then tumbled by 174444.44% in 2025.
  • Orchestra BioMed Holdings' Cash from Financing Activities (Quarter) stood at -$5.1 million in 2022, then crashed by 110.14% to -$10.7 million in 2023, then surged by 230.39% to $13.9 million in 2024, then soared by 447.77% to $76.4 million in 2025.
  • Its Cash from Financing Activities was $76.4 million in Q3 2025, compared to -$428000.0 in Q2 2025 and -$296000.0 in Q1 2025.